Get the Stockscreener App
7.94
2.34%
-0.19
After Hours:
7.97
0.03
+0.38%
Kyverna Therapeutics Inc stock is traded at $7.94, with a volume of 1.28M.
It is down -2.34% in the last 24 hours and up +1.79% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$8.13
Open:
$8.11
24h Volume:
1.28M
Relative Volume:
0.90
Market Cap:
$473.28M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-2.5644
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
-15.08%
1M Performance:
+1.79%
6M Performance:
+182.56%
1Y Performance:
+108.40%
1-Day Range:
$7.7696
$8.255
1-Week Range:
$7.7696
$9.55
52-Week Range:
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
7.94 | 484.60M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Trendlines Converge — Decision Point for The Ruby Mills LimitedAnalyst Downgrades & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
Twin Insider Buys Signal Major Confidence in Kyverna Therapeutics - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares - MarketBeat
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock - MarketBeat
Kyverna Therapeutics director Seidenberg buys $999,997 in shares By Investing.com - Investing.com Nigeria
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 By Investing.com - Investing.com Australia
Kyverna Therapeutics director Seidenberg buys $999,997 in shares - Investing.com
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 - Investing.com
Kyverna Therapeutics Insider Bought Shares Worth $999,998, According to a Recent SEC Filing - marketscreener.com
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 11.68% to 28.76 - Nasdaq
Will Kyverna Therapeutics Inc. stock recover faster than peers2025 EndofYear Setup & Verified Swing Trading Watchlists - Улправда
Institution Moves: What margin trends mean for Kyverna Therapeutics Inc. stockForecast Cut & Community Trade Idea Sharing - ulpravda.ru
Why Kyverna Therapeutics Inc. stock is rated strong buy2025 Market Outlook & Weekly Stock Breakout Alerts - Улправда
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Kyverna Therapeutics Inc. stock attractive after correction2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Market Leaders: What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Pullbacks & Accurate Buy Signal Alerts - ulpravda.ru
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Is Kyverna Therapeutics Inc. stock near bottom after declineGDP Growth & Growth Focused Stock Pick Reports - DonanımHaber
Kyverna Therapeutics announces $100 million public offering - MSN
Is Kyverna Therapeutics Inc. stock attractive after correctionDollar Strength & Daily Stock Trend Reports - ulpravda.ru
What is the fair value of Kyverna Therapeutics Inc. stock nowMarket Volume Summary & Real-Time Market Sentiment Alerts - DonanımHaber
Will Kyverna Therapeutics Inc. stock see PE expansionQuarterly Growth Report & Fast Moving Trade Plans - DonanımHaber
Aug PostEarnings: How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Highlights & High Accuracy Investment Signals - ulpravda.ru
What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Earnings & High Yield Equity Trading Tips - Улправда
How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Snapshot & Low Risk High Win Rate Picks - ulpravda.ru
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies (NASDAQ:KYTX) - Seeking Alpha
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects - Yahoo Finance
Kyverna Therapeutics Announces $100 Million Public Offering - TipRanks
Kyverna Therapeutics Signs Underwriting Agreement With J.P. Morgan, Leerink Partners and Morgan Stanley - TradingView — Track All Markets
Kyverna Therapeutics (NASDAQ:KYTX) CTO Karen Marie Walker Sells 23,998 Shares - MarketBeat
Kyverna Therapeutics CTO Karen Marie Walker Sells Shares - TradingView — Track All Markets
Officer Walker Sells 23,998 ($292.8K) Of Kyverna Therapeutics Inc [KYTX] - TradingView — Track All Markets
Kyverna Therapeutics Shares Drop After Public Offering - StocksToTrade
Kyverna Therapeutics stock plunges after $100 million share offering By Investing.com - Investing.com Nigeria
Kyverna Therapeutics stock plunges after $100 million share offering - Investing.com India
Transcript : Kyverna Therapeutics, Inc.Special Call - marketscreener.com
Kyverna Therapeutics announces pricing of $100M public offering - MSN
Kyverna Therapeutics prices public offering of common stock at $7.50 - Investing.com
Kyverna Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
Kyverna Therapeutics announces pricing of $100 million public offering - marketscreener.com
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):